Journal: Advanced Healthcare Materials

Article Title: Plasma‐Polymerized Nanoparticles Presenting Fibrillin‐1 Drive Rapid Re‐Endothelialization of Vascular Grafts

doi: 10.1002/adhm.202503360

Figure Lengend Snippet: PPN‐PF8 functionalization of ePTFE improves endothelial attachment in vitro. A) Representative images of SEM and F‐actin staining. B) HCAEC attachment and C) spreading on ePTFE, ePTFE with passively bound PF8 (ePTFE‐PF8), PPN‐coated ePTFE (PPN), and PPN‐PF8 functionalized ePTFE, n = 3 per sample. Scale bar = 300 µm. * p < 0.05, *** p < 0.001 versus ePTFE.

Article Snippet: Human coronary artery endothelial cells (HCAEC; Cell Applications) were cultured in MesoEndo medium (Cell Applications) at 37 °C in 5% CO 2 .

Techniques: In Vitro, Staining

Journal: Advanced Healthcare Materials

Article Title: Plasma‐Polymerized Nanoparticles Presenting Fibrillin‐1 Drive Rapid Re‐Endothelialization of Vascular Grafts

doi: 10.1002/adhm.202503360

Figure Lengend Snippet: PPN‐PF8 functionalization of ePTFE improves endothelial proliferation in vitro. A) Representative images of SEM and F‐actin staining of HCAEC proliferation on days 1 and 3. B) HCAEC proliferation and C) spreading on ePTFE, ePTFE with passively bound PF8, PPN, and PPN‐PF8 functionalized ePTFE. * p < 0.05, *** p < 0.001 versus ePTFE on each day, Scale bar = 300 µm. n = 3 per sample.

Article Snippet: Human coronary artery endothelial cells (HCAEC; Cell Applications) were cultured in MesoEndo medium (Cell Applications) at 37 °C in 5% CO 2 .

Techniques: In Vitro, Staining

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Protective role of N-acetylcysteine and Sulodexide on endothelial cells exposed on patients’ serum after SARS-CoV-2 infection

doi: 10.3389/fcimb.2023.1268016

Figure Lengend Snippet: Intracellular generation of free radicals in CAEC exposed to culture medium (Medium), culture medium supplemented with 20% control serum (Control), 20% Post-COVID-19-serum (Post-COVID), 20% Post-COVID-19 serum supplemented with N-Acetylcysteine 1 mmol/L (Post-COVID+NAC), or Post-COVID-19 serum with Sulodexide 0.5 LRU/mL (Post-COVID+Sul).

Article Snippet: During the experiments, the primary cultures of human coronary artery endothelial cells (CAEC) obtained from Cell Applications, Inc. (San Diego, California, USA) were used.

Techniques: Control

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Protective role of N-acetylcysteine and Sulodexide on endothelial cells exposed on patients’ serum after SARS-CoV-2 infection

doi: 10.3389/fcimb.2023.1268016

Figure Lengend Snippet: Synthesis of IL-6 (A) and vWF (B) in CAEC exposed to culture medium (Medium), culture medium supplemented with 20% control serum (Control), 20% Post-COVID-19 serum (Post-COVID), 20% Post-COVID-19 serum supplemented with N-Acetylcysteine 1 mmol/L (Post-COVID+NAC), or Post-COVID-19 serum with Sulodexide 0.5 LRU/mL (Post-COVID+Sul).

Article Snippet: During the experiments, the primary cultures of human coronary artery endothelial cells (CAEC) obtained from Cell Applications, Inc. (San Diego, California, USA) were used.

Techniques: Control

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Protective role of N-acetylcysteine and Sulodexide on endothelial cells exposed on patients’ serum after SARS-CoV-2 infection

doi: 10.3389/fcimb.2023.1268016

Figure Lengend Snippet: Synthesis of tPA (A) and PAI-1 (B) in CAEC exposed to culture medium (Medium), culture medium supplemented with 20% control serum (Control), 20% Post-COVID-19 serum (Post-COVID), 20% Post-COVID-19 serum supplemented with N-Acetylcysteine 1 mmol/L (Post-COVID+NAC),or Post-COVID-19 serum with Sulodexide 0.5 LRU/mL (Post-COVID+Sul).

Article Snippet: During the experiments, the primary cultures of human coronary artery endothelial cells (CAEC) obtained from Cell Applications, Inc. (San Diego, California, USA) were used.

Techniques: Control

Journal: Journal of Translational Medicine

Article Title: Quinic acid regulated TMA/TMAO-related lipid metabolism and vascular endothelial function through gut microbiota to inhibit atherosclerotic

doi: 10.1186/s12967-024-05120-y

Figure Lengend Snippet: QA improved TMAO-induced inflammatory lesions and endothelial dysfunction in HCAECs. (A) CCK-8 was applied to detect the toxicity of QA on HCAECs. (B) CCK-8 was used to detect HCAECs proliferation. (C) The expression of COX-2, IL-6, E-selectin, ICAM-1, HMGB1 was detected by RT-qPCR. (D) The expression of p-P65, p-MAPK14 protein was detected by western blot. (E) HMGB1 levels were detected by ELISA. (F) The expression of ZO-2, VE-Cadherin and Occludin were detected by western blot. * P < 0.05 vs. Control, # P < 0.05 vs. TMAO

Article Snippet: To investigate the cytotoxicity of QA, human coronary artery endothelial cells (HCAECs, HUM-iCell-c006, iCell) were treated with 1, 2.5, 5, 10 and 20 μM QA.

Techniques: CCK-8 Assay, Expressing, Quantitative RT-PCR, Western Blot, Enzyme-linked Immunosorbent Assay, Control

Journal: bioRxiv

Article Title: miR-10b Deficiency Affords Atherosclerosis Resistance

doi: 10.1101/248641

Figure Lengend Snippet: A. Nucleotide sequences of miR-10b and those of its target in 3’ UTR in LTBP1. B. Western blotting for LTBP1 and β-tubulin (TUBB) using various human ECs that showed Type-I phenotypes (HUVEC, HAEC, HCAEC, HMVEC and ESdEC[P6]) and those with Type-II phenotypes (iPS(BJ)EC, iPS(HU)EC, ESdEC[P0] and ESdEC[P1]) as reported previously 1 . C . Type-II ECs that were transfected with an empty vector (CMV-vector (+), mock) or an miR-10b expression vector (CMV-vector (+), miR-10b), and Type-II ECs without transfection (CMV-vector (-)) were subjected to Western blotting for using an anti-LTBP1 body or an anti-β-tubulin (TUBB) antibody. D . Western blotting for LTBP1 and β-tubulin (TUBB) proteins using Type-I ECs that were transfected with a control HIV vector (control) or an miR-10b inhibitor-expressing HIV vector (miR-10bi) together with Western blotting using Type-II ECs without transfection were shown as indicated. E. Proliferation indexes of SMCs that were co-cultured with Type-II ECs in the absence or the presence of increasing concentrations of LY2157299, a TGF-β signaling inhibitor, as indicated. N=3. F and G . SMCs were co-cultured with Type-I or Type-II ECs and the percentages of phosphorylated SMAD2/3-positive cells in were calculated by flow cytometry (F) and nuclear localization of SMAD3 in PKH-26 (red)-stained SMCs was estimated by immunostaining studies with an anti-smad3 antibody (green) along with nuclear counterstaining with DAPI (blue) (G). Full-length blots are presented in Supplementary information. Abbreviations: ESdEC[P6], human ES cell-derived ECs at passage 6; ESdEC[P0], human ES cell-derived ECs at passage 0; ESdEC[P1], human ES cell-derived ECs at passage 1.

Article Snippet: Human umbilical vein endothelial cells (HUVEC), human aortic endothelial cells (HAEC), human microvascular endothelial cells (HMVEC) and human coronary arterial endothelial cells (HCAEC) were purchased from Dainippon Sumitomo Pharma Co., Ltd. (Osaka Japan).

Techniques: Western Blot, Transfection, Plasmid Preparation, Expressing, Cell Culture, Flow Cytometry, Staining, Immunostaining, Derivative Assay